MX351471B - Derivados de piridinona y pirimidinona como inhibidores del factor xia. - Google Patents

Derivados de piridinona y pirimidinona como inhibidores del factor xia.

Info

Publication number
MX351471B
MX351471B MX2014007269A MX2014007269A MX351471B MX 351471 B MX351471 B MX 351471B MX 2014007269 A MX2014007269 A MX 2014007269A MX 2014007269 A MX2014007269 A MX 2014007269A MX 351471 B MX351471 B MX 351471B
Authority
MX
Mexico
Prior art keywords
pyridinone
factor xia
xia inhibitors
pyrimidinone derivatives
inhibitors
Prior art date
Application number
MX2014007269A
Other languages
English (en)
Other versions
MX2014007269A (es
Inventor
Ichihara Osamu
Suzuki Ryo
Courtney Steve
Yarnold Chris
Flanagan Stuart
Brace Gareth
Barker John
Gadouleau Elise
Richardson Anthony
Kondo Takashi
Imagawa Akira
Nakatani Shingo
Kouyama Sho
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1122139.7A external-priority patent/GB2497806A/en
Priority claimed from GB201217290A external-priority patent/GB201217290D0/en
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2014007269A publication Critical patent/MX2014007269A/es
Publication of MX351471B publication Critical patent/MX351471B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula general (I), sus sales y N-óxidos, y solvatos y profármacos de los mismos (en donde los caracteres son como se definen en la descripción). Los compuestos de la fórmula general (I) son inhibidores del Factor XIa de manera que son útiles en la prevención de y/o terapia para enfermedades tromboembólicas. (ver Fórmula).
MX2014007269A 2011-12-21 2012-12-20 Derivados de piridinona y pirimidinona como inhibidores del factor xia. MX351471B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
GB201217290A GB201217290D0 (en) 2012-09-27 2012-09-27 Compounds
PCT/GB2012/053217 WO2013093484A1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors

Publications (2)

Publication Number Publication Date
MX2014007269A MX2014007269A (es) 2014-07-22
MX351471B true MX351471B (es) 2017-10-17

Family

ID=47553259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007269A MX351471B (es) 2011-12-21 2012-12-20 Derivados de piridinona y pirimidinona como inhibidores del factor xia.

Country Status (23)

Country Link
US (2) US9732085B2 (es)
EP (2) EP3290413B9 (es)
JP (2) JP6137193B2 (es)
KR (1) KR102011534B1 (es)
CN (1) CN104136431B (es)
AU (1) AU2012356374B2 (es)
BR (1) BR112014015669B1 (es)
CA (1) CA2859604C (es)
DK (1) DK2794597T3 (es)
ES (2) ES2655669T3 (es)
HK (1) HK1198386A1 (es)
HU (1) HUE036010T2 (es)
IL (1) IL233154A (es)
IN (1) IN2014CN04676A (es)
MX (1) MX351471B (es)
NO (1) NO2794597T3 (es)
PH (1) PH12014501365B1 (es)
PL (1) PL2794597T3 (es)
PT (1) PT2794597T (es)
RU (1) RU2630677C2 (es)
SG (1) SG11201403402VA (es)
TW (1) TWI613199B (es)
WO (1) WO2013093484A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183153A1 (en) 2010-02-11 2012-09-27 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
EP2733144B1 (en) * 2011-07-13 2016-01-06 Santen Pharmaceutical Co., Ltd Novel compound having parp inhibitory activity
IN2014CN02805A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2625256T3 (es) 2011-10-14 2017-07-19 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 ＸＩａ 억제제로서 피리디논 및 피리미디논 유도체
WO2013096637A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2014014050A1 (ja) 2012-07-19 2014-01-23 大日本住友製薬株式会社 １－（シクロアルキルカルボニル）プロリン誘導体
TW201410667A (zh) 2012-08-03 2014-03-16 必治妥美雅史谷比公司 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑
TW201410666A (zh) 2012-08-03 2014-03-16 必治妥美雅史谷比公司 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
KR102143257B1 (ko) 2012-10-12 2020-08-10 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제의 결정질 형태
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
EP2978425B1 (en) * 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
EP3024822B1 (de) * 2013-07-23 2017-05-03 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia und plasmakallikrein inhibitoren
US9765070B2 (en) * 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
NO2760821T3 (es) 2014-01-31 2018-03-10
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3104702B1 (en) 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Factor xia inhibitors
WO2015120777A1 (zh) * 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2015164308A1 (en) 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
WO2016015593A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
CN104311537B (zh) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途
WO2016046158A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN106687458B (zh) * 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
PT3231803T (pt) * 2014-12-10 2020-09-03 Ono Pharmaceutical Co Derivado de di-hidroindolizinona
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
RU2649141C2 (ru) * 2015-04-20 2018-03-30 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
RU2653511C2 (ru) * 2015-07-29 2018-05-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие
KR20180031037A (ko) 2015-08-05 2018-03-27 브리스톨-마이어스 스큅 컴퍼니 신규 치환된 글리신 유도된 fxia 억제제
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
CN108430471B (zh) 2015-10-29 2021-07-09 默沙东公司 因子XIa抑制剂
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
TWI756257B (zh) * 2016-08-31 2022-03-01 大陸商江蘇恆瑞醫藥股份有限公司 吡啶酮醯胺類衍生物、其製備方法及其在醫藥上的應用
DE202017006776U1 (de) 2016-10-07 2018-05-16 Mitsubishi Hitec Paper Europe Gmbh Wärmeempfindliches Aufzeichnungsmaterial
EP3305538A1 (de) 2016-10-07 2018-04-11 Mitsubishi HiTec Paper Europe GmbH Wärmeempfindliches aufzeichnungsmaterial
CN106950319B (zh) * 2017-04-20 2019-08-30 西安科技大学 一种检测特鲁曲班光学异构体含量的方法
CN109507345B (zh) * 2017-09-15 2022-08-05 万特制药(海南)有限公司 重酒石酸卡巴拉汀中间体及其杂质的分离测定方法
CA3091528A1 (en) * 2018-02-27 2019-09-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of oxopicolinamide derivative and preparation method therefor
WO2020007256A1 (zh) 2018-07-02 2020-01-09 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及制备方法
TWI825144B (zh) * 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
CN111727186B (zh) * 2018-11-11 2022-11-08 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
KR20210097119A (ko) * 2018-11-30 2021-08-06 오노 야꾸힝 고교 가부시키가이샤 (3s)-3-[2-(6-아미노-2-플루오로피리딘-3-일)-4-플루오로-1h-이미다졸-5-일]-7-[5-클로로-2-(1h-테트라졸-1-일)페닐]-2,3-디히드로인돌리진-5(1h)-온의 신규 결정
CN109836360B (zh) * 2019-03-19 2021-08-13 南京恩泰医药科技有限公司 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物
CN112028877B (zh) * 2019-06-04 2021-11-26 江西济民可信集团有限公司 烷氧吡啶酮化合物及其制备方法和用途
WO2020259668A1 (zh) * 2019-06-28 2020-12-30 上海济煜医药科技有限公司 三并环类化合物及其制备方法和用途
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd FXA INHIBITORS AND METHODS OF PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF
CN112778277B (zh) * 2019-11-11 2024-04-02 江西济民可信集团有限公司 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
US20230312560A1 (en) * 2020-07-22 2023-10-05 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
WO2023002984A1 (ja) * 2021-07-20 2023-01-26 小野薬品工業株式会社 イミダゾール化合物の製造方法
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US20230097157A1 (en) * 2021-07-22 2023-03-30 Janssen Pharmaceutica Nv Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
CN113735770B (zh) * 2021-09-30 2023-06-06 四川大学 一种铑催化的4-苯基噁二唑酮与碳酸亚乙烯酯合成1-氨基异喹啉骨架的方法
WO2023179624A1 (zh) * 2022-03-21 2023-09-28 上海济煜医药科技有限公司 三并环类化合物制备方法及其中间体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042675A1 (en) 1980-06-20 1981-12-30 Norton Company Method of mounting a grinding wheel on a spindle
EP0222425A3 (en) 1982-05-18 1988-09-21 University Of Florida Brain-specific drug delivery
CA1241120A (en) 1985-10-01 1988-08-23 Sami A. Aly Alternate mark inversion (ami) receiver
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
DE4407488A1 (de) 1994-03-07 1995-09-14 Bayer Ag Verwendung von Biphenyl- und Pyridylmethylpyridonen
BR0307631A (pt) 2002-02-14 2004-12-21 Pharmacia Corp Piridinonas substituìdas como moduladores de p38 map-quinase
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0518126A (pt) 2004-10-15 2008-10-28 Astrazeneca Ab composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
ES2380632T3 (es) 2004-11-24 2012-05-17 Vertex Pharmceuticals Incorporated Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas
WO2007016354A1 (en) 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
ATE511502T1 (de) 2005-12-14 2011-06-15 Bristol Myers Squibb Co Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
KR20090085117A (ko) * 2006-11-24 2009-08-06 다케다 야쿠힌 고교 가부시키가이샤 헤테로모노시클릭 화합물 및 이의 용도
JP5342450B2 (ja) * 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
WO2009076337A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
ES2380648T3 (es) * 2008-03-13 2012-05-17 Bristol-Myers Squibb Company Derivados de piridazina como inhibidores del factor XIA
BRPI1008473A2 (pt) 2009-02-06 2019-04-02 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
UY33650A (es) * 2010-10-07 2012-04-30 Takeda Pharmaceutical Compuestos heterocíclicos
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 ＸＩａ 억제제로서 피리디논 및 피리미디논 유도체

Also Published As

Publication number Publication date
HUE036010T2 (hu) 2018-06-28
AU2012356374A8 (en) 2014-08-07
CN104136431B (zh) 2017-03-15
US9732085B2 (en) 2017-08-15
HK1198386A1 (en) 2015-04-17
PL2794597T3 (pl) 2018-03-30
BR112014015669A8 (pt) 2017-07-04
EP3290413B1 (en) 2019-11-13
IN2014CN04676A (es) 2015-09-18
NO2794597T3 (es) 2018-04-14
RU2014129797A (ru) 2016-02-10
PH12014501365A1 (en) 2014-09-22
PH12014501365B1 (en) 2014-09-22
US10717738B2 (en) 2020-07-21
NZ626176A (en) 2015-09-25
TW201339157A (zh) 2013-10-01
JP6447660B2 (ja) 2019-01-09
CA2859604A1 (en) 2013-06-27
EP3290413B9 (en) 2020-04-29
KR102011534B1 (ko) 2019-08-16
EP2794597A1 (en) 2014-10-29
AU2012356374A1 (en) 2014-07-10
CN104136431A (zh) 2014-11-05
SG11201403402VA (en) 2015-01-29
JP2017160239A (ja) 2017-09-14
RU2630677C2 (ru) 2017-09-12
AU2012356374B2 (en) 2017-06-22
US20170305917A1 (en) 2017-10-26
ES2765891T3 (es) 2020-06-11
BR112014015669B1 (pt) 2021-10-13
PT2794597T (pt) 2018-01-16
JP6137193B2 (ja) 2017-05-31
US20150152112A1 (en) 2015-06-04
ES2655669T3 (es) 2018-02-21
WO2013093484A1 (en) 2013-06-27
JP2015500868A (ja) 2015-01-08
TWI613199B (zh) 2018-02-01
KR20140103286A (ko) 2014-08-26
CA2859604C (en) 2019-12-17
IL233154A0 (en) 2014-08-03
BR112014015669A2 (pt) 2017-06-13
IL233154A (en) 2016-12-29
EP2794597B1 (en) 2017-11-15
MX2014007269A (es) 2014-07-22
EP3290413A1 (en) 2018-03-07
DK2794597T3 (en) 2018-01-15

Similar Documents

Publication Publication Date Title
MX351471B (es) Derivados de piridinona y pirimidinona como inhibidores del factor xia.
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
PH12017502141A1 (en) Compounds and their methods of use
PH12016501388A1 (en) Heteroaryls and uses thereof
MX2013012979A (es) Piridina y derivados de pirazina.
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
PH12015501038A1 (en) Inhibitors of iap
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration